The clinical safety and efficacy of selinexor combined with venetoclax and azactitidine induction therapy in relapsed and refractory acute myeloid leukemia
10.3760/cma.j.cn121090-20231031-00241
- VernacularTitle:塞利尼索联合维奈克拉、阿扎胞苷方案诱导治疗复发难治急性髓系白血病的疗效及安全性观察
- Author:
Li'na LIU
1
;
Yushan CUI
;
Yuzhang LIU
;
Yaomei WANG
;
Pu XIANG
;
Lijie LIANG
;
Yiran LI
;
Baijun FANG
Author Information
1. 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008
- From:
Chinese Journal of Hematology
2024;45(8):772-775
- CountryChina
- Language:Chinese
-
Abstract:
To determine the efficacy and safety of selinexor combined with venetoclax (VEN) and azactitidine (AZA) for patients with relapsed and/or refractory acute myeloid leukemia (R/R AML) . Twelve patients with R/R AML treated with selinexor plus VEN and AZA in the Affiliated Cancer Hospital of Zhengzhou University from May 2022 to May 2023 were included. Their clinical data were retrospectively analyzed. Among the 12 R/R AML patients, 5 (41.7%) achieved complete remission (CR) , 1 (8.3%) achieved CR with incomplete hematological recovery, and 5 (41.7%) achieved partial remission. The median time to reach CR was 28 (16-59) days. The median PFS was 61 (15-300) days. The main adverse event of the regimen was hematological toxicity. No chemotherapy-related deaths were observed. The combination of selinexor plus VEN and AZA is an effective treatment for R/R AML patients.
